不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
DLBCL 以外淋巴瘤中 CAR-T 治疗的新适应证与平台
英文原题：New Indications and platforms for CAR-T therapy in lymphomas beyond DLBCL.
查看英文原题
New Indications and platforms for CAR-T therapy in lymphomas beyond DLBCL.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CD19 靶向CAR-T 细胞疗法（CAR-T）代表了复发/难治性大 B 细胞淋巴瘤（LBCL）患者的重大进展。长期随访证实，近半数患者可获得持久缓解，而这一人群此前估计接受标准挽救治疗的中位生存期约为 6 个月。CAR-T 的这一初步成功促使其在其他淋巴瘤组织学类型中的显著扩展，近期已导致 CAR-T 在套细胞淋巴瘤和滤泡性淋巴瘤中获得监管批准。此外，多种新型 CAR-T 治疗平台正在开发中，以提高疗效并限制毒性，例如双抗原靶向、异基因和自然杀伤 CAR。在这篇综述中，我们重点关注 CAR-T 在 LBCL 以外淋巴瘤中的新适应症以及新兴的 CAR-T 治疗平台。
展开英文摘要原文
CD19 directed chimeric antigen receptor T-cell therapy (CAR-T) represents a significant advancement for patients with relapsed/refractory large B-cell lymphoma (LBCL). Long term follow-up confirms durable remissions in nearly half of the patients, a population which was previously estimated to have a median survival of around 6 months with standard salvage therapy.
This initial success of CAR-T has led to significant expansion across other lymphoma histologies resulting in the recent regulatory approval of CAR-T in mantle cell lymphoma and follicular lymphoma.
Additionally, multiple novel platforms of CAR-T therapy are under development to improve efficacy and limit toxicity such dual antigen targeting, allogeneic and natural killer CAR's. In this review, we focus on the new indications of CAR-T in lymphomas beyond LBCL as well as emerging platforms of CAR-T therapy.
论文信息
- 作者
- Iqbal M、Savani BN、Hamadani M
- 第一作者单位
- Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL.United States
- 通讯作者单位
- Blood & Marrow Transplantation and Cellular Therapy Program, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI.United States
- 期刊
- EJHaem2022 Jan
- 原文标识
- PubMed 34988550 · DOI 10.1002/jha2.323
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →